Sort
10,766 grants matching “checkpoint inhibitor”
In situ radioimmunotherapy to maximize the engagement of conventional type 1 dendritic cells against non-T cell-inflamed tumors
$400,868Fumito Ito · University Of Southern California · R01 · FY2023 · CA
Protective role of Clec7a/dectin-1 in CNS autoimmunity
$400,857Mari L. Shinohara · Duke University · R01 · FY2025 · NS
Kinetochore Structure and Function
$400,813Institute For Cancer Research · R01 · FY2003 · GM
Immune Regulation of Lung Squamous Metastasis
$400,580Chad V Pecot · Univ Of North Carolina Chapel Hill · R01 · FY2017 · CA
Mesenchymal Cell Dysfunction in Fibroproliferative Lung Disease
$400,551Paul Wesley Noble · Cedars-Sinai Medical Center · P01 · FY2018 · HL
Targeting Lag-3 and PD -1 in Myeloid Cells of GBM
$400,345Michael Lim · Stanford University · R01 · FY2023 · NS
qHTS of Patient Derived HCC Models to Identify Novel Probes/Therapeutic Agents
$400,283Paul A. Johnston · University Of Pittsburgh At Pittsburgh · R01 · FY2019 · CA
Targeting the Immunosuppressive Tumor Microenvironment for Colorectal Cancer Treatment
$400,276Qingding Wang · University Of Kentucky · R01 · FY2023 · CA
Targeting the Immunosuppressive Tumor Microenvironment for Colorectal Cancer Treatment
$400,276Qingding Wang · University Of Kentucky · R01 · FY2025 · CA
Project 1:Therapeutically improving HNSCC antigenicity through epigenetic reprogramming
$400,078Sara Isabel Pai · Massachusetts General Hospital · P01 · FY2022 · CA
Project 2: Redirecting pre-existing anti-viral immunity to HNSCCs with APECs
$400,074Thorsten Roman Mempel · Massachusetts General Hospital · P01 · FY2022 · CA
Development of a DISE-inducing, short RNA therapeutic to treat ovarian cancer
$400,000Robert Schickel · Nuago Therapeutics Inc · R42 · FY2025 · CA
SIRPant Technology for anti-Cancer Immunity
$400,000Nathanael McCurley · Sirpant Immunotherapeutics, Inc. · R42 · FY2021 · CA
Evaluation of lead FANA oligos targeting FOXP3, with and without anti-PD-1 mAb, as an approach for cancer immunotherapy
$400,000Veenu Aishwarya · Aum Lifetech, Inc. · R43 · FY2022 · CA
Development of polymeric synthetic biomaterial IP-001 to potentiate asystemic immunotherapy of hepatocellular carcinoma via thermal ablation
$400,000Siu Kit Lam · Immunophotonics, Inc. · R44 · FY2021 · CA
The immunosuppressive function of Checkpoint kinase 2 in gliomas
$400,000Crismita Clement Dmello · Northwestern University At Chicago · R01 · FY2024 · NS
Developing a Novel Biologic Therapy to Eradicate Brain Cancer and Brain Metastasis
$400,000Donald Davidson · Creative Biotherapeutics, Llc · R43 · FY2024 · CA
Mechanism and therapeutic potential of microglia regulation in glioblastoma
$400,000Peiwen Chen · Northwestern University At Chicago · R01 · FY2023 · NS
Extended half-life GlyTR1 combined with checkpoint blockade for Cancer Immunotherapy
$400,000Michael Demetriou · Glytr Therapeutics, Inc. · R42 · FY2023 · CA
First in Human Phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy
$400,000Pan Zheng · Oncoimmune, Inc. · R44 · FY2020 · CA
Development of Anti-EGFR-huEndo-P125A: A combined Vasculogenic Mimicry-Angiogenesis inhibitory therapeutic for Triple Negative Breast Cancer
$400,000Rathin C Das · Synergys Biotherapeutics, Inc. · R44 · FY2022 · CA
Mechanism and therapeutic potential of microglia regulation in glioblastoma
$400,000Peiwen Chen · Northwestern University At Chicago · R01 · FY2022 · NS
A Novel Lentivector for Enhanced In Vivo Delivery of T Cell Receptors for Cell Therapy for Stage IV Melanoma
$400,000David Scott Johnson · Gigamune, Inc. · R44 · FY2025 · CA
The Immunosuppressive Function of Checkpoint Kinase 2 in Gliomas
$400,000Crismita Clement Dmello · Northwestern University At Chicago · R01 · FY2025 · NS
Optimization of TIL Cell Manufacturing for Cancer Treatment
$400,000Soon Seog Jeong · Human Cell Co · R43 · FY2023 · CA